retatrutide clinical trial phase ๐จBreaking: Retatrutide's first 3 T2D data just dropped. โธ A1C: โ2.0% at 40 weeks โธ Weight: โ36.6 lbs (โ16.8%) at 12 mg โธ No weight loss plateau โ curve still descending Lilly's retatrutide delivers promising results
Description
Los alimentos que aumentan el GLP-1 son las protenas como carne, pescado y huevos
GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d
NEJS
The ever-expanding popularity of GLP-1 drugs for weight loss is challenging employers to balance access and cost.
Retatrutide is not currently approved by the Therapeutic Goods Administration (TGA) for therapeutic use in Australia the compound remains in clinical-trial development
Complete QuickFill once (clinic header, links, and global placeholders)
